Genetic mutations in tumor cells cause several unique metabolic phenotypes that are critical
for cancer cell proliferation. Mutations in the tyrosine kinase epidermal growth factor receptor …

Oncogenic epidermal growth factor receptor (EGFR) signaling plays an important role in
regulating global metabolic pathways, including aerobic glycolysis, the pentose phosphate …

Oncogenic EGFR is essential for the development and growth of non–small cell lung cancer
(NSCLC), but the precise roles of EGFR in lung cancer metabolism remain unclear. Here …

Cancer cells exhibit increased use of nutrients, including glucose and glutamine, to support
the bioenergetic and biosynthetic demands of proliferation. We tested the small-molecule …

Purpose: One of the hallmarks of cancer cells is the excessive conversion of glucose to
lactate under normoxic conditions, also known as the Warburg effect. Here, we tested …

Use of epidermal growth factor receptor (EGFR) inhibitors represented by gefitinib and
erlotinib has become the standard of treatment for non-small-cell lung cancers (NSCLCs) …

The microenvironment influences cancer drug response and sustains resistance to
therapies targeting receptor-tyrosine kinases. However, if and how the tumor …

One of the biggest hurdles for the development of metabolism-targeted therapies is to
identify the responsive tumor subsets. However, the metabolic vulnerabilities for most …

Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

The secondary EGF receptor (EGFR) T790M is the most common mechanism of resistance
to reversible EGFR-tyrosine kinase inhibitors (TKI) in patients with non–small cell lung …